SCHEMBL5357868

SCHEMBL5357868

COc1cc2c(=O)c(-c3noc(Cc4ccc(C)cc4)n3)cn(Cc3ccc(Cl)cc3)c2cc1OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 4/20 0.52
KMT2A Q03164 4/20 0.52
TSHR P16473 3/20 0.52
MEN1 O00255 2/20 0.52
LMNA P02545 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
SMN1; SMN2 Q16637 5/20 0.47
TP53 P04637 3/20 0.47
POLB P06746 1/20 0.47
RAB9A P51151 3/20 0.46
TDP1 Q9NUW8 3/20 0.46
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
ALOX12 P18054 2/20 0.46
NTSR1 P30989 1/20 0.46
ATM Q13315 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
ALOX15 P16050 1/20 0.45
MAPT P10636 4/20 0.44
NPC1 O15118 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5353454 0.93 KMT2A (0.52) MAPK1KMT2ATSHRMEN1LMNA
SCHEMBL5346943 0.88 KMT2A (0.47) MAPK1KMT2ATSHRMEN1LMNA
SCHEMBL5344829 0.86 MAPT (0.45) MAPK1KMT2ATSHRMEN1LMNA
SCHEMBL14386939 0.84 KMT2A (0.43) MAPK1KMT2ATSHRMEN1LMNA
SCHEMBL5370074 0.84 TP53 (0.45) MAPK1KMT2ATSHRMEN1LMNA
SCHEMBL5356153 0.83 TP53 (0.44) MAPK1KMT2ATSHRMEN1LMNA
SCHEMBL5353654 0.82 LMNA (0.55) MAPK1KMT2ATSHRMEN1LMNA
SCHEMBL5355486 0.79 USP10 (0.51) MAPK1KMT2ATSHRMEN1LMNA
SCHEMBL5354226 0.77 MAPT (0.45) KMT2AMEN1LMNASMN1; SMN2TP53
SCHEMBL5361237 0.77 ALDH1A1 (0.52) MAPK1KMT2ATSHRMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070287699-A1 ANTIVIRAL AGENTS VIROBAY, INC. (US) 2007-12-13 US disclosed
US-20070287699-A1 ANTIVIRAL AGENTS VIROBAY, INC. (US) 2007-12-13 US disclosed
US-20070287699-A1 ANTIVIRAL AGENTS VIROBAY, INC. (US) 2007-12-13 US disclosed
WO-2007130499-A2 ANTIVIRAL AGENTS VIROBAY, INC. (US) 2007-11-15 WO disclosed
WO-2007130499-A2 ANTIVIRAL AGENTS VIROBAY, INC. (US) 2007-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287699-A1 ANTIVIRAL AGENTS EIF2AK2, MAVS, ZC3HAV1 MAPK1 4356/4885KMT2A 4280/4885TSHR 4409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.